Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04378569 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
A Phase 1 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 230
- Enrollment target
NCT04378569: Completed Phase 1 study, sponsored by Arcutis Biotherapeutics.
NCT04378569 is a Phase 1 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 230 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (283% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04378569, a Phase 1 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 230 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema
Primary Outcome
The number of Cohort 1 participants with an AE is reported. An AE is any untoward or unfavorable medical occurrence in a human participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to participation in the research.
Interventions
- DRUG ARQ-252 cream 0.3%
- DRUG ARQ-252 cream 0.1%
- DRUG ARQ-252 Vehicle Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2021-02-24 |
| Phase | Phase 1 |
What the finished NCT04378569 record still lists
NCT04378569 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (283% higher).
The record links to 0 conditions, and to 3 interventions - of which ARQ-252 cream 0.3% is the first listed.
NCT04378569 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04378569 about?
NCT04378569 is a clinical study titled "Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema". This study will assess the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema
What is the current status of trial NCT04378569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 230 participants. The study started on 2020-04-20. Estimated completion is 2021-02-24.
What interventions are being tested in trial NCT04378569?
The interventions under investigation include: ARQ-252 cream 0.3% (DRUG), ARQ-252 cream 0.1% (DRUG), ARQ-252 Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT04378569?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04378569's enrollment target sits among peer trials
230 219th of 2000 higher than 1,780 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI